Trial sponsors have shared these lung cancer clinical trials that are enrolling participants to help advance lung cancer science. Most medications and treatments currently available are thanks to patients who went through clinical trials to prove the effectiveness and safety of the treatment being studied.

Clinical trials have eligibility requirements to join so that participants remain safe, while having a likelihood of success when it comes to treatment.

If you’re interested in joining one of the clinical trials below, make sure to talk with your doctor and ask if they think it would be helpful for your treatment. Some patients may have additional health problems that could be made worse by treatments used in a clinical trial.

Note: The status of each trial may change with time. Please reach out to the contact listed in each trial opportunity to get the most up-to-date information. 

Available clinical trials

  • LIVIGNO-4

    Contact:

    Jeffrey Sobolow, [email protected]

    Full title: LIVIGNO-4: Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

    Description:

    The LIVIGNO-4 Study is a Phase 2/3 clinical study of a combination of two investigational medications (“study drugs”), with standard-of-care chemotherapy, for non-squamous NSCLC. The study will look at the safety of the combination and if it works for non-squamous NSCLC without actionable genomic alterations that has grown or spread and has not been treated. The study drugs livmoniplimab and budigalimab are investigational. Livmoniplimab and budigalimab are monoclonal antibodies that may target specific substances in the body that help cancer to grow and spread. The combination of livmoniplimab and budigalimab is hypothesized to result in increased anti-cancer activity

    Who can participate?

    You can participate if you:

    • have a diagnosis of metastatic non-squamous NSCLC, and 
    • have either not received systemic treatment for metastatic non-squamous NSCLC, or
    • have received systemic treatment such as chemotherapy or radiation for early-stage lung cancer and saw no growth or return of the cancer within 6 months after stopping treatment

     

    Learn more

*These trials are listed for a period of 3 months.